Cyclin D1 degradation is sufficient to induce G1 cell cycle arrest despite constitutive expression of cyclin E2 in ovarian cancer cells

Cancer Research

Volumn 69, Issue 16, 2009, Pages 6565-6572

  Masamha, Chioniso Patience ^a   Benbrook, Doris Mangiaracina ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLIN E; CYCLIN E2; GLYCOGEN SYNTHASE KINASE 3BETA; P21 ACTIVATED KINASE; PROTEASOME; PROTEIN P53; SHETA2; TRANSCRIPTION FACTOR DP1; TRANSCRIPTION FACTOR E2F; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; COMPLEX FORMATION; CONTROLLED STUDY; ENZYME DEGRADATION; GENE OVEREXPRESSION; GENE SILENCING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; KNOCKOUT GENE; OVARY CANCER; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; PROTEIN TARGETING; UBIQUITINATION;

APOPTOSIS; CELL PROLIFERATION; CHROMANS; CYCLIN D1; CYCLINS; DRUG EVALUATION, PRECLINICAL; FEMALE; G1 PHASE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOGEN SYNTHASE KINASE 3; HUMANS; OVARIAN NEOPLASMS; PHOSPHORYLATION; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN PROCESSING, POST-TRANSLATIONAL; THIONES; TRANSFECTION; TUMOR CELLS, CULTURED; UBIQUITINATION;

EID: 69249155033     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-0913     Document Type: Article

References (41)

1. D'Andrilli G, Kumar C, Scambia G, Giordano A. Cell cycle genes in ovarian cancer: steps toward earlier diagnosis and novel therapies. Clin Cancer Res 2004;10:8132-41.
2. Brewer MA, Johnson K, Follen M, Gershenson D, Bast R, Jr. Prevention of ovarian cancer: intraepithelial neoplasia. Clin Cancer Res 2003;9:20-30.
3. Brewer M, Wharton JT, Wang J, et al. In vitro model of normal immortalized ovarian surface epithelial and ovarian cancer cells for chemoprevention of ovarian cancer. Gynecol Oncol 2005;98:182-92.
4. Sun SY, Hail N, Jr., Lotan R. Apoptosis as a novel target for cancer chemoprevention. J Natl Cancer Inst 2004;96: 662-72.
5. Macaluso M, Paggi MG, Giordano A. Genetic and epigenetic alterations as hallmarks of the intricate road to cancer. Oncogene 2003;22:6472-8.
6. Rubin SM, Gall AL, Zheng N, Pavletich NP. Structure of the Rb C-terminal domain bound to E2F1-DP1: a mechanism for phosphorylation-induced E2F release. Cell 2005;123:1093-106.
7. Bali A, O'Brien PM, Edwards LS, Sutherland RL, Hacker NF, Henshall SM. Cyclin D1, p53, and p21Waf1/Cip1 expression is predictive of poor clinical outcome in serous epithelial ovarian cancer. Clin Cancer Res 2004;10:5168-77.
8. Knudsen KE, Diehl JA, Haiman CA, Knudsen ES. Cyclin D1: polymorphism, aberrant splicing and cancer risk. Oncogene 2006;25:1620-8.
9. Vermeulen K, Van Bockstaele DR, Berneman ZN. The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif 2003;36:131-49.
10. Diehl JA, Zindy F, Sherr CJ. Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin-proteasome pathway. Genes Dev 1997;11:957-72.
11. Arnold A, Papanikolaou A. Cyclin D1 in breast cancer pathogenesis. J Clin Oncol 2005;23:4215-24.
12. Barbieri F, Lorenzi P, Ragni N, et al. Overexpression of cyclin D1 is associated with poor survival in epithelial ovarian cancer. Oncology 2004;66:310-5.
13. Worsley SD, Ponder BAJ, Davies BR. Overexpression of cyclin D1 in epithelial ovarian cancers. Gynecol Oncol 1997;64:189-95.
14. Yang K, Hitomi M, Stacey DW. Variations in cyclin D1 levels through the cell cycle determine the proliferative fate of a cell. Cell Div 2006;1:32.
15. 1-S phase progression. J Biol Chem 2004;279:5387-96.
16. Chen Z, Duan RS, Zhu Y, et al. Increased cyclin E expression may obviate the role of cyclin D1 during brain development in cyclin D1 knockout mice. J Neurochem 2005;92:1281-4.
17. Bowe DB, Kenney NJ, Adereth Y, Maroulakou IG. Suppression of Neu-induced mammary tumor growth in cyclin D1 deficient mice is compensated for by cyclin E. Oncogene 2002;21:291-8.
18. Yasmeen A, Berdel WE, Serve H, Muller-Tidow C. Eand A-type cyclins as markers for cancer diagnosis and prognosis. Expert Rev Mol Diagn 2003;3:617-33.
19. Yang CS, Chin KV, Lambert JD. Cancer chemoprevention by targeting proteasomal degradation. Commentary re: KA Dragnev, Pitha-Rowe I, Ma Y, et al. Clin Cancer Res 2004;10:2220-21. Clin Cancer Res 2004;10: 2570-7.
20. Verschuren EW, Jones N, Evan GI. The cell cycle and how it is steered by Kaposi's sarcoma-associated herpesvirus cyclin. J Gen Virol 2004;85:1347-61.
21. Thoms HC, Dunlop MG, Stark LA. CDK4 inhibitors and apoptosis: a novel mechanism requiring nucleolar targeting of RelA. Cell Cycle 2007;6:1293-7.
22. Benbrook DM, Kamelle SA, Guruswamy SB, et al. Flexible heteroarotinoids ( flex-hets) exhibit improved therapeutic ratios as anti-cancer agents over retinoic acid receptor agonists. Invest New Drugs 2005;23: 417-28.
23. Benbrook DM, Lightfoot S, Ranger-Moore J, et al. Gene expression analysis of biological systems driving an organotypic model of endometrial carcinogenesis and chemoprevention. Gene Regul Syst Biol 2008;2: 21-42.
24. Liu T, Hannafon B, Gill L, Kelly W, Benbrook D. Flex-hets differentially induce apoptosis in cancer over normal cells by directly targeting mitochondria. Mol Cancer Ther 2007;6:1814-22.
25. Liu S, Brown CW, Berlin KD, et al. Synthesis of flexible sulfur-containing heteroarotinoids that induce apoptosis and reactive oxygen species with discrimination between malignant and benign cells. J Med Chem 2004;47:999-1007.
26. Mic FA, Molotkov A, Benbrook DM, Duester G. Retinoid activation of retinoic acid receptor but not retinoid X receptor is sufficient to rescue lethal defect in retinoic acid synthesis. Proc Natl Acad Sci U S A 2003; 100:7135-40.
27. Myers T, Chengedza S, Lightfoot S, et al. Flexible heteroarotinoid ( flex-het) SHetA2 inhibits angiogenesis in vitro and in vivo. Invest New Drugs [serial on the Internet]. 2008 Sep [cited 2009 May 14];[about 15p.]. Available from: http://www.springerlink.com/content/aj864j6707w47513/.
28. Vermeulen K, Berneman ZN, Van Bockstaele DR. Cell cycle and apoptosis. Cell Prolif 2003;36:165-75.
29. Okabe H, Lee SH, Phuchareon J, Albertson DG, McCormick F, Tetsu O. A critical role for FBXW8 and MAPK in cyclin D1 degradation and cancer cell proliferation. PLoSONE [serial on the Internet]. 2006 Dec [cited 2009 May 13];1:[about 12p.]. Available from: http://www.pubmedcentral.nih.gov/ articlerender.fcgi?artid=1762433.
30. Debernardis D, Sire EG, De Feudis P, et al. p53 status does not affect sensitivity of human ovarian cancer cell lines to paclitaxel. Cancer Res 1997;57:870-4.
31. Wang Y, Wiltshire T, Senft J, Reed E, Wang W. Irofulven induces replication-dependent CHK2 activation related to p53 status. Biochem Pharmacol 2007;73: 469-80.
32. Alao JP. The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention. Mol Cancer 2007;6:1-16.
33. Diehl JA, Cheng M, Roussel MF, Sherr CJ. Glycogen synthase kinase-3h regulates cyclin D1 proteolysis and subcellular localization. Genes Dev 1998;12:3499-511.
34. Schmitz NMR, Leibundgut K, Hirt A. CDK2 catalytic activity and loss of nuclear tethering of retinoblastoma protein in childhood acute lymphoblastic leukemia. Leukemia 2005;19:1783-7.
35. Hershenson MB. p21Waf1/Cip1 and the prevention of oxidative stress. Am J Physiol Lung Cell Mol Physiol 2004;286:L502-5.
36. Gladden AB, Diehl JA. Location, location, location: the role of cyclin D1 nuclear localization in cancer. J Cell Biochem 2005;96:906-93.
37. Yam CH, Fung TK, Poon RYC. Cyclin A in cell cycle control and cancer. Cell Mol Life Sci 2002;59:1317-26.
38. Salas TR, Reddy SA, Clifford JL, et al. Alleviating the suppression of glycogen synthase kinase-3h by Akt leads to the phosphorylation of cAMP-response elementbinding protein and its transactivation in intact cell nuclei. J Biol Chem 2003;278:41338-46.
39. Freemantle SJ, Guo Y, Dmitrovsky E. Retinoid chemoprevention trials: cyclin D1 in the crosshairs. Cancer Prev Res 2009;2:3-6.
40. Malumbres M, Pevarello P, Barbacid M, Bischoff JR. CDK inhibitors in cancer therapy: what is next? Trends Pharmacol Sci 2008;29:16-21.
41. McInnes C. Progress in the evaluation of CDK inhibitors as anti-tumor agents. Drug Discov Today 2008;13:875-81.